ArticleJournal of the Egyptian National Cancer Institute2025
Effect of cyclophospamide, doxorubicin, vincristine and prednisone/prednisolone (CHOP) chemotherapy regimens on left ventricular systolic function and cardiac structural abnormalities in non-Hodgkin lymphoma patients.
Article in Journal of the Egyptian National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe cyclophospamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) regimen, a standard treatment for aggressive non-Hodgkin lymphoma (NHL), is effective but linked to chemotherapy-induced cardiotoxicity (CDIC), such as heart failure and left ventricular dysfunction. Anthracyclines like doxorubicin are key contributors to CDIC. This study examines left ventricular dysfunction and structural abnormalities in NHL patients receiving CHOP therapy with cumulative doxorubicin doses ≥ 250 mg/m
methodsThis prospective cohort study was conducted at Dr. Soetomo Regional General Hospital, Surabaya, from June to October 2023. We included NHL patients aged 18-60 years at any stage, treated with CHOP regimens containing cumulative doxorubicin doses ≥ 250 mg/m
resultsA total of 32 patients, aged 46.62 ± 16.64 years, were included, with the colli region and stage 2 NHL being the most common. Significant differences were observed in all parameters between pre- and post-chemotherapy. LVEF decreased by - 2.40% ± 1.79 (p < 0.001), while global longitudinal strain (GLS) declined by 2.25 ± 1.36 (p < 0.001). HS troponin I levels showed a significant increase of 17.27 ± 36.29 (p < 0.001), and NT-proBNP levels rose by 321.23 ± 85.34 (p < 0.001). The study also identified a higher risk of cardiotoxicity in patients over 50 years of age.
conclusionThe CHOP regimen poses significant risks of subclinical cardiac dysfunction and structural abnormalities in NHL patients, with cumulative doxorubicin dosage being a key contributor. Early detection using sensitive biomarkers like GLS and NT-proBNP is crucial for identifying cardiotoxicity and enabling timely interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.